🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Which genes should be tested in pts w BC? ESMO - Eur. Oncology working group concludes that selected genes based on potential likely cancer-specific related mortality benefits are BRCA1, BRCA2, PALB2, RAD51C, RAD51D (BRIP1) and TP53; equivocal survival benefit for ATM and CHECK2. OncoAlert

Answer: pts with BRCA mutations (germinal or somatic) experience worse outcomes with T-DXd given for mBC rwPFS: 7.8 vs 9.2 mo (HR 1.4, p=0.02) Consistent with findings from DB03/04. Reasons unclear. Grateful with Dana-Farber’s Breast Oncology Center & Yale COPPER Center colleagues for this collaboration.

Some more 💰slides from #ESMOBreast25 via Yakup Ergün featuring Debate conclusions on CDK4/6i beyond PD , translational research and ADCs #bcsm

Top 10 Breast Cancer Trials to Watch at #ASCO25 Save the date ⏰ Big data in HER2+, TNBC & HR+ mBC! 1️⃣ DESTINY-Breast09 – T-DXd+P vs THP (1L HER2+ MBC) [LBA] 2️⃣ ASCENT-04 – SG+pembro vs chemo+pembro (1L TNBC) [LBA] 3️⃣ SERENA-6 – Camizestrant+CDK4/6i in ESR1mut HR+ ABC [LBA] 4️⃣

One week to #ASCO25. Which will be an unprecedented ASCO for breast oncologists. Treatment algorithms will change for ALL disease subtypes. ADCs will climb to earlier lines of treatment. Paradigms will be challenged. Here’s my list of top 10 abstracts. See you in Chicago! #bcsm

Finally the #ASCO25 abstracts are available online....it's going to be a super important ASCO for #BreastCancer ! OncoAlert Conquer Cancer, the ASCO Foundation The ASCO Post Link: meetings.asco.org/abstracts-pres…

The #ASCO25 abstracts I cannot wait to see!

First-line ribociclib + trastuzumab + letrozole (without chemo) for HR+/HER2+ mBC shows mPFS 30.4 months and mOS not reached Small trial (n=66 pts) #ASCO25 OncoAlert

Rapid oral mBC #ASCO25 OptiTROP-Breast05: Sac-TMT shows 70% ORR and 13.4 mo PFS as 1st-line therapy in advanced TNBC (incl. pts with PD-L1–negative, CPS <10). Promising efficacy with no neuropathy or ILD. 2 phase III trials now underway in PD-L1–negative mTNBC. OncoAlert

Cowabunga! Riding Breast Cancer's Biggest Data's Wave 🏄🏻‍♂️🌊🤙🏻from ASCO25 PF-07248144, first-in-class KAT6 inhibitor, shows 37.2% ORR + 15.8 months response duration in ER+/HER2- metastatic breast cancer post-CDK4/6i! Phase 3 ready! 🎯 OncoAlert #ASCO25

Thrilled to share our latest review in Cancer Treatment Reviews on navigating therapy after CDK4/6 inhibitor progression in HR+/HER2- MBC. 🧬 Clinical & genomic factors 🔬 ESR1 & PIK3CA mutations 🎯 Targeted strategies for better outcomes 📖 Read more: doi.org/10.1016/j.ctrv…

Kudos to ASCO for being mommy-friendly! Nursing rooms are: ✅close to the main conference rooms ✅private ✅well equipped and comfy Bonus point for best badge ever! 🥰 #ASCO25 #family #breastfeeding #workingmom

Cowabunga! Riding Breast Cancer's Biggest Data's Wave 🏄🏻‍♂️🌊🤙🏻from ASCO25 BRCA BCY reveals MT type matters! In 3,294 young BRCA+ BC pts: truncating variants=worse OS (HR 2.00 for BRCA1), missense variants=better prognosis.🧬 Terrific speaker Angela Toss OncoAlert #ASCO25

Today has been one of the most exciting days of my life. I'm deeply grateful to all the colleagues who supported the realization of this analysis — especially Matteo Lambertini, MD PhD, one of the most visionary and altruistic people I’ve ever met. #ASCO2025

Angela Toss Matteo Lambertini, MD PhD Thank you Angela and all other Italian colleagues for making us proud of your performance at this #ASCO25

Dear Colleagues at #ASCO25 An honor to present Angela Toss Presenting on Association between type of BRCA1/2 pathogenic/likely pathogenic variants and outcome in young patients with #BreastCancer Eva Blondeaux Cynthia Villarreal-Garza, MD DSc Carmine De Angelis Elisa Agostinetto Breast Cancer

At #ASCO25 Clinical Science Symposium Angela Toss🇮🇹presented new insights from the 🌍BRCA BCY collab on the impact of BRCA variant #types in young pts with BC (n=3,294) Key findings: Truncating BRCA 1 PVs = worse OS Missense BRCA1/2 PVs = better OS Matteo Lambertini, MD PhD OncoAlert

📌 Clinical Science Symposium Diving Deeper to Inform Hereditary Cancer Risk and Outcomes 🧬Association between type of BRCA1/2 pathogenic/likely pathogenic variants and outcome in young patients with breast cancer: 🔹Results from an international cohort study.🔹 ✨Angela Toss

Another money 💰 slide from #asco25 ASCO . Treatment algorithm for HR +/ HER 2 -ve mBC OncoAlert Kate Sears

Thank you Matteo Lambertini, MD PhD for organizing this annual event! Wonderful to see a growing number of new participants along with several familiar faces, confirming the sustained growth of the #YBO community 📈 See you all next year! ♥️